[go: up one dir, main page]

IT8520271A0 - Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. - Google Patents

Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.

Info

Publication number
IT8520271A0
IT8520271A0 IT8520271A IT2027185A IT8520271A0 IT 8520271 A0 IT8520271 A0 IT 8520271A0 IT 8520271 A IT8520271 A IT 8520271A IT 2027185 A IT2027185 A IT 2027185A IT 8520271 A0 IT8520271 A0 IT 8520271A0
Authority
IT
Italy
Prior art keywords
antianoxic
pharmaceutical compositions
metabolic action
cerebral metabolic
cerebral
Prior art date
Application number
IT8520271A
Other languages
English (en)
Other versions
IT1201412B (it
Inventor
Alberto Bertelli
Original Assignee
Seuref Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seuref Ag filed Critical Seuref Ag
Publication of IT8520271A0 publication Critical patent/IT8520271A0/it
Application granted granted Critical
Publication of IT1201412B publication Critical patent/IT1201412B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IT20271/85A 1984-04-09 1985-04-05 Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale IT1201412B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1774/84A CH661438A5 (it) 1984-04-09 1984-04-09 Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.

Publications (2)

Publication Number Publication Date
IT8520271A0 true IT8520271A0 (it) 1985-04-05
IT1201412B IT1201412B (it) 1989-02-02

Family

ID=4218293

Family Applications (1)

Application Number Title Priority Date Filing Date
IT20271/85A IT1201412B (it) 1984-04-09 1985-04-05 Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale

Country Status (7)

Country Link
US (1) US4684520A (it)
JP (1) JPS6133118A (it)
CH (1) CH661438A5 (it)
DE (1) DE3417857C2 (it)
FR (1) FR2562422B1 (it)
GB (1) GB2157171B (it)
IT (1) IT1201412B (it)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661443A5 (en) * 1984-11-22 1987-07-31 Seuref Ag Pharmaceutical compositions having metabolic activity
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
JPH01305032A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 機能後退性消耗疾患治療予防剤及び飲食、し好物
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
US6461593B1 (en) * 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
WO1994015595A1 (en) * 1993-01-06 1994-07-21 Jemo-Pharm A/S Medium comprising a pharmacological/biological active substance
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6441050B1 (en) * 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
JP2004513183A (ja) * 2000-11-14 2004-04-30 バイタル ヘルス サイエンシズ プロプライアタリー リミティド リン酸誘導体の複合体
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
CN1547475B (zh) * 2001-07-27 2010-12-15 生命健康科学有限公司 含电子转移试剂的磷酸酯衍生物的皮肤制剂
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20060241085A1 (en) * 2003-01-17 2006-10-26 West Simon M Compounds having anti-proliferative properties
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US8252322B2 (en) * 2003-06-03 2012-08-28 Corn Products Development, Inc. Delivery system with increased bioavailability
TW200524541A (en) * 2003-11-17 2005-08-01 Cargill Inc Lecithin-containing granular compositions and methods of their preparation
US20060069157A1 (en) * 2004-02-19 2006-03-30 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, by sodium butyrate chemotherapy
BRPI0508125A (pt) * 2004-03-03 2007-07-17 Vital Health Sciences Pty Ltd formulação de alcalóide, método para melhorar a eficácia de um alcalóide, uso do produto da reação de um ou mais alcalóides com um mais derivados de fosfato de um ou mais agentes de transferência de elétrons, junto com excipientes e composição farmacêutica
EP1799242A4 (en) * 2004-09-16 2009-11-11 Univ California TYPE G PEPTIDES AND OTHER ACTIVE SUBSTANCES TO REDUCE ATHEROSCLEROSIS AND OTHER DISEASES
US7901675B2 (en) * 2004-10-13 2011-03-08 U.S. Department Of Veterans Affairs Method of using coenzyme Q10 to treat Huntington's disease
EP1827472A4 (en) 2004-12-06 2012-09-05 Univ California METHODS FOR IMPROVING THE STRUCTURE AND FUNCTION OF ARTERIOLES
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
CA2599424A1 (en) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
NZ580954A (en) * 2005-04-29 2011-05-27 Univ California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
KR20080019228A (ko) * 2005-06-17 2008-03-03 바이탈 헬스 사이언시즈 피티와이 리미티드 하나 이상의 디 및/또는 모노-(전자전달제) 인산염 유도체또는 그의 착염을 함유하는 담체
DE102005056558B4 (de) * 2005-11-25 2009-04-30 Gisela Susilo Kombinationspräparate enthaltend physiologische Zellmembran-Bestandteile
WO2007070981A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
GB0603975D0 (en) * 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
US20090192312A1 (en) * 2006-04-10 2009-07-30 Mitsubishi Gas Chemical Company, Inc. Brain Function-Improving Agent, and Functional Food Containing the Improving Agent
AU2007322948A1 (en) * 2006-11-22 2008-05-29 Asahi Kasei Pharma Corporation Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
TWI507193B (zh) 2010-03-30 2015-11-11 Phosphagenics Ltd 經皮輸送貼劑
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINO-QUINOLINES AS KINASE INHIBITORS
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
JP6882321B2 (ja) 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
CA3045702A1 (en) 2016-12-21 2018-06-28 Phosphagenics Limited Phosphorylation process of complex alcohols

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938202B2 (ja) * 1976-03-05 1984-09-14 エーザイ株式会社 難聴治療剤
JPS5356315A (en) * 1976-11-01 1978-05-22 Eisai Co Ltd Emulsified solution of fat soluble drugs
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
FR2472384A1 (fr) * 1979-12-27 1981-07-03 Sederma Sa Utilisation en cosmetologie de complexes naturels constitues d'ubiquinones et de phospholipides
JPS5742616A (en) * 1980-08-27 1982-03-10 Furointo Sangyo Kk Ubiquinone pharmaceutical having improved absorption
JPS5775916A (en) * 1980-10-29 1982-05-12 Nippon Chemiphar Co Ltd Coenzyme q pharmaceutical and its preparation
JPS57142911A (en) * 1981-02-28 1982-09-03 Furointo Sangyo Kk Absorption-improving agent
JPS58113127A (ja) * 1981-12-28 1983-07-05 Ajinomoto Co Inc ユビデカレノン含有水性液
CH649917A5 (en) * 1982-03-19 1985-06-28 Italfarmaco Sa Pharmaceutical formulations containing the coenzyme Q(10) suitable for topical administration
JPS58201711A (ja) * 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体

Also Published As

Publication number Publication date
JPH0530813B2 (it) 1993-05-11
CH661438A5 (it) 1987-07-31
IT1201412B (it) 1989-02-02
DE3417857A1 (de) 1985-10-17
GB2157171A (en) 1985-10-23
US4684520A (en) 1987-08-04
JPS6133118A (ja) 1986-02-17
GB2157171B (en) 1988-07-06
GB8508452D0 (en) 1985-05-09
DE3417857C2 (de) 1997-04-24
FR2562422B1 (fr) 1989-03-31
FR2562422A1 (fr) 1985-10-11

Similar Documents

Publication Publication Date Title
IT8520271A0 (it) Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
FI850323A0 (fi) Heterocykliska kompositioner.
FI844903L (fi) Anordning foer att slao in en artikel med en toejbar plastfilm.
IT1197061B (it) Composizioni farmaceutiche ad azione vasodilatatrice e antianossica
IT1209615B (it) Composizione farmaceutica
IT1187756B (it) Isoindolinil-alchil-piperazine ad attivita' farmaceutica
DE3579623D1 (de) Wegweiser.
IT8721063A0 (it) Composizione ad attivita'tricogena.
IT1214648B (it) 8 alfa-acilamminoergoline,loro preparazione e loro impiego come medicamenti
IT1214641B (it) Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
DK330584D0 (da) Paedagogisk legesaet
FI850954A0 (fi) Anordning vid teleskoparmar.
IT1186667B (it) 2,1,3-benzotiadiazoli e 2,1,3-benzossadiazoli,loro preparazione e loro applicazione come medicamenti
IT8420082A0 (it) Agenti ad attivita'antibroncospastica e composizioni farmaceutiche che li contengono.
AT380411B (de) Kugelmuehle
IT8547704A1 (it) Diazepinoindoli loro preparazione e loro impiego come medicamenti
IT1194677B (it) Composizione farmaceutica ad attivita' antiflogistica,antipiretica e antalgica
DE3577324D1 (de) Polysiloxanzusammensetzung.
AT380410B (de) Kugelmuehle
IT8422088A0 (it) Xantinilmetil-tiazolidine e composizioni farmaceutiche che le contengono.
IT8319957A0 (it) Composizione ad attivita'atabagica.
IT1152378B (it) Composizione farmaceutica ad attivita' antiemorragica
IT1157291B (it) Composizione farmaceutica ad attivita' antiemicranica
IT1155354B (it) Composizione farmaceutica ad attivita' antiulcera
IT1170241B (it) Composizioni farmaceutiche ad attivita' antibatterica-immunostimolante

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19990331